FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Related Topics >> Vaccine | brain cancer | glioblastoma

Brain cancer vaccine a success in mid-stage trial

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


An experimental dendritic cell vaccine for glioblastoma multiforme--a lethal brain cancer--has demonstrated a successful immune response in a key study. And following a vaccination with chemotherapy significantly increased the time to tumor progression, according to a report in Cancer Research. Out of 32 patients in the mid-stage trial, 17 experienced a significant positive response after three vaccinations. The average length of survival was 21 months for responders compared to 14 months for non-responders.

"Fifty-three percent of patients in our study exhibited a significant vaccine-enhanced immune response. Compared to non-responders or those with limited responses, the vaccine responders had significantly longer times to tumor progression and longer survival," said Cedars-Sinai's Department of Neurosurgery Chairman Dr. Keith L. Black.

"No other vaccine trial in cancer patients has shown the kind of progressive correlation between immune responses and clinical outcomes that we found," said Christopher J. Wheeler, a research scientist at the Maxine Dunitz Neurosurgical Institute.

- read the report in the Washington Post

Related Articles:
Brain cancer vaccine doubles survival time
New vaccine/chemo combo effective in cancer study
Kennedy's surgery may be followed by experimental therapy

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Vaccine   brain cancer   glioblastoma  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.